AMGN

#70
Amgen Inc
345.65 USD
-1.51%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
344.21
345.86
Rango anual
261.43
391.29
Cambio diario
-1.51%
Variación mensual
-6.42%
Variación en los últimos 6 meses
+15.79%
Cambio anual
+17.27%
Cierres anteriores
350.95
Abrir
345.50
Bid
Ask
Mínimo
344.21
High
345.86
Volumen
435
Ver el calendario completo

Financials

Visión general Informes Estadísticas Dividendos
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Amgen Inc

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Noticias